Endoplasmic Reticulum Aminopeptidase 2, a common immunological link to adverse pregnancy outcomes and cancer clearance?
Endoplasmic Reticulum Aminopeptidase 2, a common immunological link to adverse pregnancy outcomes and cancer clearance?
复制标题
DOI：
10.1016/j.placenta.2017.03.012
复制
发表时间：
2017-08-01
期刊：
影响因子：
3.8
通讯作者：
Lee, Eun D.
中科院分区：
文献类型：
--
作者：
Lee, Eun D.
内质网氨肽酶2（ERAP 2）修整HLA I类结合肽，决定免疫识别的肽库。ERAP 2氨基酸序列的变异可能会影响一些胎儿和肿瘤实现免疫逃避的能力。例如，在母亲和胎儿中从未检测到ERAP 2变体的纯合性，其增加了疏水分子的修剪效率。因此，ERAP 2基因中的这种单核苷酸多态性（SNP）可能被选择以防止免疫特权子宫环境的改变，并允许肿瘤逃避免疫识别。目前，没有免疫治疗或预防方法来确保健康的妊娠结局，并且癌症免疫治疗的成功是可变的。了解ERAP 2在妊娠和癌症中的免疫逃避机制中的作用可能会提高胎儿存活率和肿瘤清除率。本文综述了ERAP 2及其N392变异体与妊娠结局和癌症免疫逃避/识别的关系。(C)2017作者出版社：Elsevier Ltd
Endoplasmic Reticulum Aminopeptidase 2 (ERAP2) trims HLA class I-binding peptides, determining the peptide repertoire presented for immune recognition. Variation in the ERAP2 amino acid sequence could affect the ability of some fetuses and tumors to achieve immune evasion. For example, homozygosity for an ERAP2 variant that has increased trimming efficiency for hydrophobic molecules has never been detected in mothers and fetuses. Thus, it is possible that this single nucleotide polymorphism (SNP) in the ERAP2 gene has been selected against in order to prevent alteration of the immune privileged uterine environment, and to allow tumors to escape immune recognition. Currently, there are no immunological treatments or prophylactic approaches to ensure a healthy pregnancy outcome, and the success of cancer immunotherapies is variable. Understanding the role of ERAP2 in immune evasion mechanisms in pregnancy and cancer may improve fetal survival and tumor clearance. This review summarizes current knowledge about ERAP2 and its N392 variant, and their relationship to pregnancy outcomes and cancer immune evasion/recognition. (C) 2017 The Author. Published by Elsevier Ltd.